Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats

DE Gmerek, A Cowan and JH Woods

The individual contributions of central (brain) and peripheral (enteric) sites in the mediation of the systemic actions of opioids are not well established. In this study, we made use of naltrexone methobromide, a quaternary analog of naltrexone, to separate the central and peripheral components of the slowing action of morphine on gastrointestinal transit in rats. It was established that i.c.v., but not s.c., administration of quaternary naltrexone antagonized morphine- induced analgesia in the radiant-heat tail-flick assay in rats. Thus, quaternary naltrexone probably does not enter the central nervous system in significant amounts after systemic administration. Systemic quaternary naltrexone antagonized, in a dose-related manner, the delaying effects of morphine on the movement of a charcoal meal along the gastrointestinal tract. Quaternary naltrexone was 30 or 100 times less potent than naltrexone when administered s.c. or i.c.v., respectively. Unlike naltrexone, quaternary naltrexone antagonized morphine-induced slowing of gastrointestinal transit only when administered by the same route (i.e., both s.c. or both i.c.v.). The apparent pA2 for s.c. quaternary naltrexone against s.c. morphine was not significantly different from the apparent pA2 for i.c.v. quaternary naltrexone against i.c.v. morphine. Distinct and independent central and peripheral systems appear to mediate morphine-induced inhibition of gastrointestinal transit in rats. However, the receptors are probably of the same type. Peripherally selective antagonists such as quaternary naltrexone may be useful in reversing morphine-induced inhibition of gastrointestinal transit without affecting analgesia.

Volume 236, Issue 1, pp. 8-13, 01/01/1986
Copyright © 1986 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C.-S. Yuan Methylnaltrexone Mechanisms of Action and Effects on Opioid Bowel Dysfunction and Other Opioid Adverse Effects Ann. Pharmacother., June 1, 2007; 41(6): 984 - 993. [Abstract] [Full Text] [PDF]

				M.-C. Ko, E. R. Butelman, J. R. Traynor, and J. H. Woods Differentiation of Kappa Opioid Agonist-Induced Antinociception by Naltrexone Apparent pA2 Analysis in Rhesus Monkeys, J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 518 - 526. [Abstract] [Full Text]

				J. Yu, E. R. Butelman, J. H. Woods, B. T. Chait, and M. J. Kreek Dynorphin A (1-8) Analog, E-2078, Crosses the Blood-Brain Barrier in Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 633 - 638. [Abstract] [Full Text]

				G. Hanks and P. Hoskin Review article : Opioid analgesics in the management of pain in patients with cancer. A review Palliative Medicine, January 1, 1987; 1(1): 1 - 25. [PDF]